目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Congestive Heart Failure Drugs Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Congestive Heart Failure Drugs Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape

Chapter 4. Congestive Heart Failure Drugs Market: Drug Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Congestive Heart Failure Drugs Market: Drug Movement Analysis, USD Million, 2023 & 2030
4.3. ACE Inhibitors
4.3.1. ACE Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Angiotensin 2 Receptor Blockers
4.4.1. Angiotensin 2 Receptor Blockers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Beta Blockers
4.5.1. Beta Blockers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Diuretics
4.6.1. Diuretics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Aldosterone antagonists
4.7.1. Aldosterone antagonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Inotropes
4.8.1. Inotropes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.9. Others
4.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Congestive Heart Failure Drugs Market: Product Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Congestive Heart Failure Drugs Market: Product Movement Analysis, USD Million, 2023 & 2030
5.3. Injection
5.3.1. Injection Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Capsule
5.4.1. Capsule Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Tablets
5.5.1. Tablets Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Congestive Heart Failure Drugs Market: Distribution Channel Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Congestive Heart Failure Drugs Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
6.3. Hospitals
6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Retail Pharmacies
6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Online Pharmacies
6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Congestive Heart Failure Drugs Market: Regional Estimates & Trend Analysis
7.1. Congestive Heart Failure Drugs Market Share, By Region, 2023 & 2030, USD Million
7.2. North America
7.2.1. North America Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. UK Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. France Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Italy Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Spain Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Denmark Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Sweden Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Norway Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. China
7.4.2.1. China Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Japan Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. India Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. South Korea Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Australia Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Thailand Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Argentina
7.5.3.1. Argentina Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. South Africa Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. UAE Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Kuwait Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. Bayer AG
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. Novartis AG
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. Merck & Co., Inc.
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. AstraZeneca
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Bristol-Myers Squibb Company
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. Amgen Inc.
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Boehringer Ingelheim International GmbH
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Pfizer, Inc.
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. Johnson & Johnson Services, Inc.
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
8.4.10. Otsuka Pharmaceutical Co., Ltd.
8.4.10.1. Participant’s Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/ Strategic Initiatives
8.4.11. Eli Lilly and Company
8.4.11.1. Participant’s Overview
8.4.11.2. Financial Performance
8.4.11.3. Product Benchmarking
8.4.11.4. Recent Developments/ Strategic Initiatives
8.4.12. Novo Nordisk A/S
8.4.12.1. Participant’s Overview
8.4.12.2. Financial Performance
8.4.12.3. Product Benchmarking
8.4.12.4. Recent Developments/ Strategic Initiatives